Cameroon
Diabetes country report 2000 — 2050
Number of adults (20–79 years) with diabetes in Cameroon (CM)
2000 | 61.1 thousand |
2011 | 501.4 thousand |
2024 | 774.2 thousand |
2050 | 1.9 million |
Cameroon is one of the 49 countries and territories in the IDF Africa Region.
Data source(s) used for the diabetes estimates in adults:
- Health of Population in Transition Research Group – Cameroon, Cameroon Burden of Diabetes (CamBoD) Project: Second Survey Report. 2007. Yaounde, Cameroon.
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | 61.1 | 501.4 | 774.2 | 1,913.8 |
Age-standardised prevalence of diabetes, % | - | 6.1 | 6.9 | 7.9 |
Proportion of people with undiagnosed diabetes, % | - | - | 73.1 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 566.0 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 1,080.2 | 2,464.3 |
Age-standardised prevalence of IFG, % | - | - | 7.9 | 8.6 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 693.2 | 1,256.5 | 2,794.2 |
Age-standardised prevalence of IGT, % | - | 8.7 | 9.8 | 10.1 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 10,829.0 | 5,439.7 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 5.0 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | 76,953.9 | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | 6.1 | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | 20,064.7 | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | 7,381.7 | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 195.1 | 427.4 |
Total diabetes-related health expenditure, ID million | - | - | 481.6 | 1,054.8 |
Diabetes-related health expenditure per person, USD | - | 109.0 | 252.0 | 223.3 |
Diabetes-related health expenditure per person, ID | - | - | 622.0 | 551.2 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 8,715.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 2,436.5 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | 6,822.0 | 9,676.4 | 13,869.6 | 29,005.9 |
Population of children and adolescents (0-19 y) | - | - | 15,213,915.0 | - |
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | 61.1 |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | 6,822.0 |
Population of children and adolescents (0-19 y) | - |